Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (RACE)

Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD

The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.

Study Overview

• Status: Completed
• Conditions: Exudative Age-Related Macular Degeneration
• Intervention / Treatment: Drug: AL-78898A; Drug: Ranibizumab

Detailed Description

The study consisted of a Screening Visit (Visit 1), a Day 0 visit (Visit 2), 6 on-therapy visits at Day 1, Weeks 1, 2, 3, 4, and 8 (Visits 3-8), and an Exit Visit at Week 12 (Visit 9). Patients who met all inclusion and exclusion criteria at Visit 1 were randomized in a 3:1 ratio to receive either AL-78898A or LUCENTIS as a single 50-μL injection in the study eye. Additionally, patients received standard therapy for exudative AMD beginning at Week 2/Visit 5 if the patient was not improving per protocol-specified criteria. Beginning at Week 4/Visit 7, patients not improving received standard therapy for exudative AMD at the investigator's discretion.

• Study Type: Interventional
• Enrollment (Actual): 99
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Texas
    • Fort Worth, Texas, United States, 76134
      • Contact Alcon Call Center for Trial Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Willing to give informed consent, make the required study visits and follow instructions;
• Newly diagnosed with exudative age-related macular degeneration (AMD);
• Presence of primary juxta- or subfoveal choroidal neovascularization (CNV) secondary to AMD (study eye);
• Best-corrected visual acuity (BCVA) in study eye as specified in protocol;
• No vision-threatening ocular condition other than AMD, in the opinion of the Investigator;
• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• History or current evidence of macular or retinal disease other than exudative AMD (study eye);
• Any evidence of fibrosis or scarring within the CNV (choroidal neovascularization)lesion (study eye);
• Any evidence of vitreous hemorrhage (study eye);
• History or evidence of surgery (study eye), as specified in protocol;
• Any active systemic infection or ocular/intraocular infection or inflammation in either eye;
• A history or current medical diagnosis of glaucoma or ocular hypertension (study eye), as specified in protocol;
• History or current evidence of a medical condition that may in the opinion of the Investigator preclude the safe administration of test article, adherence to the scheduled study visits, safe participation in the study or affect the results of the study
• History of severe or serious hypersensitivity to any component of the investigational product, reference product or clinically relevant sensitivity to fluorescein dye, as assessed by the Investigator;
• Females of childbearing potential may not participate in the study if pregnant, lactating, or not using adequate birth control methods for the duration of the study;
• Participation in any ocular or non-ocular investigational study within 30 days of screening;
• Has received any approved or investigational therapy for AMD in the study eye with the exception of vitamins;
• Other protocol-defined exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: AL-78898A; Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up	Drug: AL-78898A; Investigational treatment
ACTIVE_COMPARATOR: Lucentis; Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up	Drug: Ranibizumab; Anti-vascular endothelial growth factor (VEGF) treatment; Other Names: LUCENTIS®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4	The thickness of the retina was measured using a non-invasive device that produces cross-sectional and 3D images of the eye. The reduction was calculated by subtracting Week 4 visit value from the Baseline value. A positive number indicates a reduction in thickness compared to baseline, whereas a negative number indicates an increase in thickness. An increase in thickness as compared to baseline may indicate a progression of the underlying disease.	Week 4
Incidence of Events of Special Interest (ESI)	An ESI was a protocol-specified event of scientific and medical concern specific to the Sponsor's product or program where ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. These adverse events could have been serious or nonserious and may have required further investigation in order to characterize and understand.	Up to Day 30

Collaborators and Investigators

• Sponsor: Alcon Research
• Investigators: Study Director: Mehdi Hosseini, Alcon Research

Study record dates

Study Major Dates

• Study Start: June 1, 2011
• Primary Completion (ACTUAL): April 1, 2012
• Study Completion (ACTUAL): April 1, 2012

Study Registration Dates

• First Submitted: July 2, 2010
• First Submitted That Met QC Criteria: July 2, 2010
• First Posted (ESTIMATE): July 5, 2010

Study Record Updates

• Last Update Posted (ESTIMATE): June 4, 2013
• Last Update Submitted That Met QC Criteria: April 19, 2013
• Last Verified: April 1, 2013

More Information

Terms related to this study

• Keywords: Wet AMD; Macular Degeneration; Intravitreal Injection; VEGF treatment
• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Macular Degeneration; Wet Macular Degeneration; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Ranibizumab
• Other Study ID Numbers: C-09-067